GGrantIndex
← Leaderboards

Vsevolod Katritch

Plexus Vaccine

$6,299,280
Attributed
$14,429,223
Total exposure
15
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.4M · FY201425
$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$14,429,223 · 15

By mechanism

R01$5,456,358 · 4
UH3$1,940,013 · 1
U01$1,480,275 · 1
R61$1,325,500 · 1
UG3$1,302,218 · 2
R21$860,842 · 2

Top collaborators

Others in their field

Top investigators on “Structure

Research focus

StructurePropertyLigandsReceptorScreeningIn VivoLeadPharmaceutical PreparationsDesignCollaborationsComplexAddictionAnalogSignal TransductionPainBindingIn VitroResolutionOpioidPain ManagementPharmacologyBaseGenerationsTechnology

Grant awards (30)

Drug Development for Alzheimer's neuroinflammation$1,480,275
U01 · FY2025 · AG
Development of Angiotensin AT2 inhibitors for neuropathic pain relief$818,360
UG3 · FY2025 · NS · contact PI
Targeting the allosteric sodium site with novel probes for delta opioid receptor$656,556
R01 · FY2025 · DA
Computational approaches to discover ligands with new chemotypes and functional properties$415,000
R35 · FY2025 · GM · contact PI
Development of PAC1 receptor antagonists for the treatment of Headache Disorders$1,325,500
R61 · FY2024 · NS
Targeting the allosteric sodium site with novel probes for delta opioid receptor$664,982
R01 · FY2024 · DA
Efficient synthon-based modular screening of Giga-to-Terra-scale virtual libraries$412,500
R01 · FY2024 · GM · contact PI
Computational approaches to discover ligands with new chemotypes and functional properties$69,167
R35 · FY2024 · GM · contact PI
Targeting the allosteric sodium site with novel probes for delta opioid receptor$653,137
R01 · FY2023 · DA
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$607,440
UH3 · FY2023 · NS · contact PI
Efficient synthon-based modular screening of Giga-to-Terra-scale virtual libraries$412,500
R01 · FY2023 · GM · contact PI
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$647,556
UH3 · FY2022 · NS · contact PI
Efficient synthon-based modular screening of Giga-to-Terra-scale virtual libraries$412,500
R01 · FY2022 · GM · contact PI
Structure and Function of CB2 Receptor$763,601
R01 · FY2021 · DA
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$685,017
UH3 · FY2021 · NS · contact PI
Structure and Function of CB2 Receptor$763,601
R01 · FY2020 · DA
Structure Function of CB1 Cannabinoid Receptor$716,981
R01 · FY2020 · DA · contact PI
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$483,858
UG3 · FY2020 · NS · contact PI
Rational discovery of new DOR chemotypes to prevent addiction and overdose$355,641
R33 · FY2018 · DA · contact PI
Structure-Based Discovery Opioid Receptor Ligands and Molecules, p. 83$148,996
P01 · FY2018 · DA · contact PI
Rational discovery of new DOR chemotypes to prevent addiction and overdose$362,942
R33 · FY2017 · DA · contact PI
Structure guided design of photoselectable channelrhodopsins$219,593
R21 · FY2017 · EY
Structure-Based Discovery Opioid Receptor Ligands and Molecules, p. 83$148,996
P01 · FY2017 · DA · contact PI
Structure guided design of photoselectable channelrhodopsins$230,968
R21 · FY2016 · EY
Rational discovery of new DOR chemotypes to prevent addiction and overdose$204,187
R21 · FY2016 · DA · contact PI
Structure-Based Discovery Opioid Receptor Ligands and Molecules, p. 83$147,505
P01 · FY2016 · DA · contact PI
Rational discovery of new DOR chemotypes to prevent addiction and overdose$206,094
R21 · FY2015 · DA · contact PI
Structure-Based Discovery Opioid Receptor Ligands and Molecules, p. 83$146,651
P01 · FY2015 · DA · contact PI
Structure-Based Discovery Opioid Receptor Ligands and Molecules, p. 83$171,119
P01 · FY2014 · DA · contact PI
Rational Anthrax Vaccine with Structural Epitopes on VLP$98,000
R43 · FY2002 · AI